Benefits
Episodic memory in healthy elderly with lower memory baseline (Bensalem 2019 PIVOTAL)
Bensalem 2019 (PMID 30418521, J Gerontol A Biol Sci Med Sci 74:996-1007) — bicentric double-blind randomized placebo-controlled clinical study in 215 men and women aged 60-70 years for 6 months. Memophenol™ 600 mg/day (containing 258 mg flavonoids) vs placebo. RESULTS: Significant IMPROVEMENTS in EPISODIC MEMORY particularly in subjects with LOWER memory baseline performance. CueRA Computer Touchscreen tests (visuospatial skills, episodic memory) demonstrated effect. Foundational positive RCT with subgroup analysis showing greatest benefit for those with lower-baseline cognition. Industry-sponsored (Activ'Inside) but methodologically rigorous.
Mild cognitive impairment cognition (Lopresti 2023 6-month RCT)
Lopresti 2023 (PMID 37063535, Front Psychol 14:1144231) — 6-month two-arm parallel-group randomized double-blind placebo-controlled trial in 143 volunteers aged 60-80 with MCI. Memophenol™ 150 mg twice daily (300 mg/day) or placebo. RESULTS: Memophenol™ associated with greater improvements in PROCESSING SPEED (p=0.020), VISUOSPATIAL LEARNING (p=0.012), BRIEF-A executive function global score (p=0.046). Other cognitive domains and primary endpoint (episodic memory) NOT statistically different — important honest counter-finding. Authors: 'preliminary positive results require further investigation in robust clinical trials.'
Acute cognitive enhancement in young adults (Philip 2019)
Philip 2019 acute administration in 30 healthy students aged 18-25 years. 600 mg Memophenol™ single dose vs placebo. RESULTS: INCREASED PERFORMANCE on serial three-subtraction task. TREND TOWARD improved performance on rapid visual information processing task. Smaller acute trial supporting young adult cognitive applications. Less robust than long-term elderly trials but demonstrates broader age applicability.
Synergistic grape + blueberry polyphenol matrix
Distinguishing feature: COMBINED grape AND blueberry polyphenol extracts in single supplement. Animal studies show 3-5 FOLD INCREASE in plasma concentration of blueberry phenolic metabolites + corresponding decrease in fecal appearance when co-ingested vs delivery in isolation. Mechanism: synergistic absorption + complementary polyphenol profiles (grape: resveratrol + proanthocyanidins; blueberry: cyanidin glycosides + procyanidins).
BDNF and neurotrophic effects (preclinical)
Bensalem 2018 preclinical study (J Nutr Sci 7:e19) showed Memophenol™ administration to middle-aged mice ameliorated age-induced spatial navigation deficits, modulated neuroplasticity, INCREASED EXPRESSION of nerve growth neurotrophic factor mRNA, and increased proportion of newly generated neurons with prolongations vs control mice. Foundational mechanistic preclinical evidence.
Episodic memory + executive function combined profile
Across Bensalem 2019 (episodic memory in healthy elderly) and Lopresti 2023 (executive function in MCI), Memophenol™ shows benefits across both episodic memory and executive function — important multi-domain cognitive profile. Aging-relevant cognitive domains where intervention is most needed clinically.
Mechanism of action
Combined grape + blueberry polyphenol synergy
Grape polyphenols (resveratrol, proanthocyanidins) + blueberry polyphenols (cyanidin glycosides, pterostilbene) provide MULTI-TARGET POLYPHENOL profile. Animal data shows 3-5x increased plasma metabolite concentrations vs isolated administration — synergistic absorption mechanism. Distinguishes from single-source extracts.
BDNF and synaptic plasticity enhancement
Bensalem 2018 mouse study demonstrated INCREASED nerve growth neurotrophic factor mRNA expression with Memophenol™. Modulation of neuroplasticity, increased neurogenesis with prolongation morphology. Mechanism for age-related cognitive maintenance.
BBB penetration via diverse anthocyanin profile
Multiple anthocyanins (cyanidin, peonidin, delphinidin, malvidin glycosides) provide diverse BBB penetration profiles. Combined extract delivers more comprehensive CNS polyphenol exposure than single-source extracts.
Vascular endothelial function via NO production
Polyphenols improve endothelial NO production — better cerebral perfusion. Mechanism complementary to direct CNS effects. Both grape and blueberry components contribute.
Antioxidant via direct ROS scavenging
Comprehensive polyphenol antioxidant profile from combined extracts. Direct scavenging of hydroxyl, peroxyl, superoxide radicals plus enhancement of endogenous antioxidant defenses.
Anti-inflammatory pathway modulation
NF-κB, COX-2, iNOS suppression via polyphenol mechanisms. Reduced neuroinflammation contributing to cognitive decline.
Pterostilbene mechanism (blueberry component)
Blueberry contains PTEROSTILBENE — methylated resveratrol analog with superior bioavailability. SIRT1 activation, mitochondrial biogenesis, neuroprotection. Distinct mechanism complementing grape resveratrol.
Clinical trials
Bicentric double-blind randomized placebo-controlled clinical study (Bensalem J, Dudonne S, Etchamendy N, Pellay H, Amadieu C, Gaudout D et al. 2019, J Gerontol A Biol Sci Med Sci 74(7):996-1007, doi:10.1093/gerona/gly166, PMID 30418521).
215 men and women aged 60-70 years, healthy elderly. Memophenol™ 600 mg/day (258 mg flavonoids) vs placebo for 6 months. Computer-based cognitive testing including episodic memory and visuospatial skills.
SIGNIFICANT IMPROVEMENTS in EPISODIC MEMORY particularly in subjects with LOWER memory baseline performance. Subgroup analysis identified responder population. Foundational positive RCT supporting Memophenol™ episodic memory claims. Industry-sponsored (Activ'Inside) — important context for evidence interpretation. SUBGROUP-DEPENDENT EFFICACY important context.
Two-arm parallel-group randomized double-blind placebo-controlled trial (Lopresti AL, Smith SJ, Drummond PD, Pikkalainen V 2023, Front Psychol 14:1144231, doi:10.3389/fpsyg.2023.1144231, PMID 37063535).
143 volunteers aged 60-80 years with mild cognitive impairment (MCI). Memophenol™ 150 mg twice daily (300 mg/day) vs placebo for 6 months. Multiple cognitive assessments.
Memophenol™ associated with greater improvements in PROCESSING SPEED (p=0.020), VISUOSPATIAL LEARNING (p=0.012), BRIEF-A executive function global score (p=0.046). NO STATISTICAL DIFFERENCE in other cognitive domains including EPISODIC MEMORY (the primary outcome) — important honest counter-finding. Memophenol™ well-tolerated with no significant adverse reactions. Authors: 'preliminary positive results require further investigation in robust clinical trials.' INDUSTRY-SPONSORED (Activ'Inside provided product). Mixed results pattern.
Acute administration trial (Philip P, Sagaspe P, Taillard J, Mandon C, Constans J, Pourtau L et al. 2019).
30 healthy students aged 18-25 years. Single 600 mg Memophenol™ dose vs placebo.
INCREASED PERFORMANCE on serial three-subtraction task. TREND TOWARD improved performance on rapid visual information processing task. Smaller acute trial in younger population complementing long-term elderly evidence. Demonstrates broader age applicability.
About this ingredient
Memophenol™ is a STANDARDIZED polyphenol-rich extract combining GRAPE (Vitis vinifera) and BLUEBERRY (Vaccinium angustifolium) — developed by ACTIV'INSIDE, a French biotechnology company based in Bordeaux specializing in grape polyphenol extracts. Standardized total flavonoid content provides ~258 mg flavonoids per 600 mg dose. UNIQUE COMBINATION of grape polyphenols (resveratrol, proanthocyanidins, anthocyanins like cyanidin/peonidin/delphinidin/malvidin glycosides) and blueberry polyphenols (cyanidin glycosides, pterostilbene methylated resveratrol analog, procyanidins). SYNERGISTIC ABSORPTION: animal data shows 3-5 fold increase in plasma blueberry phenolic metabolite concentrations + corresponding decrease in fecal appearance when grape and blueberry co-ingested vs isolated administration. CLINICAL EVIDENCE BASE: BENSALEM 2019 PMID 30418521 (J Gerontol A Biol Sci Med Sci) — bicentric double-blind placebo-controlled 6-month RCT in 215 healthy elderly aged 60-70 at 600 mg/day. RESULTS: episodic memory improvements particularly in subjects with LOWER memory baseline. SUBGROUP-DEPENDENT EFFICACY pattern. LOPRESTI 2023 PMID 37063535 (Front Psychol) — 6-month two-arm RCT in 143 MCI patients at 300 mg/day. RESULTS: PROCESSING SPEED (p=0.020), VISUOSPATIAL LEARNING (p=0.012), BRIEF-A EXECUTIVE FUNCTION (p=0.046) improvements; NO statistical difference in other domains INCLUDING episodic memory (primary outcome). PHILIP 2019 acute single-dose study in 30 young adults showed serial three-subtraction task improvements + RVIP task trend. Bensalem 2018 preclinical mouse study showed BDNF mRNA expression upregulation, neuroplasticity modulation, increased neurogenesis with prolongation morphology — foundational mechanism.
MECHANISMS: combined grape + blueberry polyphenol synergy with enhanced bioavailability, BDNF and synaptic plasticity enhancement, BBB penetration via diverse anthocyanin profiles, vascular endothelial NO production, comprehensive ROS scavenging, NF-κB anti-inflammatory pathway modulation, pterostilbene SIRT1/mitochondrial mechanisms (blueberry component). EVIDENCE: 2/5 reflects: (1) Bensalem 2019 PIVOTAL 6-month RCT (n=215) with subgroup-dependent positive effects, (2) Lopresti 2023 MCI RCT with mixed positive findings (processing speed, visuospatial learning, executive function POSITIVE; primary endpoint episodic memory NEGATIVE — important honest pattern), (3) Philip 2019 acute young adult evidence, (4) Bensalem 2018 preclinical BDNF mechanism, (5) industry-sponsored evidence (Activ'Inside) — important context, (6) UNIQUE grape + blueberry synergistic absorption mechanism, (7) authors' own caution: 'preliminary positive results require further investigation in robust clinical trials.' SAFETY: Excellent — food-grade origin with no significant adverse reactions in 6-month trials. Best positioned as: (a) COGNITIVE AGING in HEALTHY ELDERLY with lower-baseline memory (responder population per Bensalem 2019 subgroup analysis), (b) MCI cognitive support for processing speed and executive function (Lopresti 2023), (c) DAILY long-term use acceptable based on safety profile, (d) NOT first-line for episodic memory specifically (Lopresti 2023 NEGATIVE primary endpoint important), (e) industry-sponsored evidence — independent replication welcomed, (f) higher-evidence than typical 'berry blend' due to standardization + multiple RCTs, (g) GRAPE + BLUEBERRY SYNERGY mechanism distinguishing feature. Honest framing: Memophenol™ has rigorous evidence base — pivotal Bensalem 2019 6-month RCT plus Lopresti 2023 MCI RCT plus Philip 2019 acute trial. The grape + blueberry synergistic absorption mechanism is biochemically interesting. HOWEVER: Lopresti 2023 NEGATIVE on PRIMARY EPISODIC MEMORY ENDPOINT in MCI is important counter-evidence — Memophenol™ benefits processing speed and executive function more reliably than episodic memory in MCI. Subgroup-dependent efficacy in Bensalem 2019 (only those with lower baseline benefit) is also important nuance. Industry sponsorship warrants caveat. Authors' own caution about 'preliminary positive results' supports balanced framing. Reasonable cognitive aging adjunct based on honest evidence interpretation.